ImmuPharma PLC (AIM:IMM) told investors its management team is heading to the JP Morgan Conference and the Biotech Showcase in San Francisco next week, 11 to 16 January.
The JP Morgan conference and Biotech Showcase are annual premier partnering events, designed to provide biotechnology companies with the opportunity to present to and connect with global Biopharma companies and investors, ImmuPharma noted.
"Attending and taking meetings at both the JP Morgan conference and the Biotech Showcase offers the opportunity to continue discussions across our whole unique portfolio and specifically with global BioPharma companies that have an interest in autoimmune diseases demonstrated within our P140 technology platform," chief executive Tim McCarthy said in a statement.
“Our focus remains on track to establish global partnering opportunities across all of our programs."
ImmuPharma highlighted that there’s been eleven licensing deals worth over $1 billion for immunology assets across the BioPharma industry from 2023 to late September 2024, and it believes the current trend suggests that Immunology and Autoimmune drug assets are becoming very highly sought by the leading BioPharma companies.